Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDendreon Completes Submission of Biologics License Application for PROVENGE
Dendreon Coproration, 11/03/09
Dendreon Corporation announced that it has completed the submission of the amended Biologics License Application for PROVENGE, the Company's lead investigational product, to the U.S. Food and Drug Administration. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate–resistant prostate cancer. If approved by the FDA, PROVENGE would represent the first product in the new therapeutic class known as active cellular immunotherapies.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Sponsor
Article Search
Sponsor